The<unk>  (CPA), a steroidal antiandrogen and progestin, including its frequent and rare side<unk> , have been studied and characterized. It is generally well-tolerated and has a mild side-effect profile, regardless of dosage, when it used as a progestin or antiandrogen in combination with an estrogen such as ethinylestradiol or estradiol valerate in women. Side<unk>  of CPA include hypogonadism and associated symptoms such as demasculinization, sexual dysfunction, infertility, and osteoporosis; breast changes such as breast tenderness, enlargement, and gynecomastia; emotional changes such as fatigue and depression; and other side<unk>  such as vitamin B12 deficiency, weak glucocorticoid<unk> , and elevated liver enzymes. Weight gain can occur with CPA when it is used at high doses. Some of the side<unk>  of CPA can be improved or fully prevented if it is combined with an estrogen to prevent estrogen deficiency. Few quantitative data are available on many of the potential side<unk>  of CPA. Pooled tolerability data for CPA is not available in the literature. At very high doses in aged men with prostate cancer, CPA can cause cardiovascular side<unk> . Rarely, CPA can produce blood clots, liver damage, excessively high prolactin levels, prolactinomas, and meningiomas. Upon discontinuation from high doses, CPA can produce adrenal insufficiency as a withdrawal<unk>
Side effects of cyproterone acetate
Side effects of bicalutamide
Progestin-induced virilization
Androgen insufficiency syndrome
Antiestrogen withdrawal response
Androgen-dependent condition
Anovulation
Anabolic-androgenic steroids abuse